Assessing Treatment Response of Glioblastoma to an HDAC Inhibitor Using Whole-Brain Spectroscopic MRI.

Tomography · 2019 · PMC6403031 · PMID 30854442

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

showed a trendP = .09so close (0.05 < p ≤ 0.1)

The cohort receiving belinostat showed a trend of improved 6-month PFS compared to the control cohort ( P = .09); however, this difference was mitigated by 12 months ( P = .45).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.